DIRS.INFO The most relevant business & tech news

☆ Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
▼ + stars: | 2023-06-26 | by ( Deena Beasley | ) www.reuters.com time to read: +2 min

Companies Eli Lilly and Co FollowJune 26 (Reuters) - Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. Lilly's Mounjaro, which is awaiting U.S. regulatory approval for treatment of obesity, targets GLP-1 as well as a second obesity-related hormone called GIP. Retatrutide targets GLP-1, GIP and the body's receptors for a third hormone, glucagon. Given the three targets, Lilly has nicknamed the drug triple G.The company reported last year that a trial of Mounjaro in people who were obese or overweight found it led to weight loss of 22.5% after 72 weeks. Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved.

Persons: Eli Lilly, Lilly's, Lilly, ” Dan Skovronsky, Deena Beasley, Deepa Babington, Cynthia Osterman Organizations: American Diabetes Association, New England, of Medicine, Thomson Locations: San Diego

Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.

Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana

☆ How promising are new drugs to treat obesity?
▼ + stars: | 2023-05-05 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

CNN —The pharmaceutical company Eli Lilly announced last week that a medication developed to treat diabetes, tirzepatide, also had a substantial effect on reducing weight. Another pharmaceutical company, Novo Nordisk, manufactures the medication semaglutide, which the FDA has already approved to treat diabetes under the brand name Ozempic and to treat obesity under the brand name Wegovy. How promising are they to treat obesity? CNN: How promising are these drugs to treat obesity? It is really important to treat obesity as the disease that it is — and having effective medications to do so is crucial.

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

CDP is seeking to finalise its bid after U.S. investment firm KKR (KKR.N) last week filed its own offer for the same Telecom Italia (TIM) asset. Two sources familiar with the matter told Reuters KKR's approach valued the venture at about 20 billion euros ($21.4 billion). Prime Minister Giorgia Meloni repeatedly said her government wants to secure public control of TIM's network. But there is no common ground yet within her administration on how to reach such a goal and it was no clear whether a CDP bid would receive the blessing of the Treasury. Economy Minister Giancarlo Giorgetti believes Rome has "multiple options" to put TIM's network under strategic government control, a separate source said, without elaborating.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Amgen says experimental obesity drug has promising durability
▼ + stars: | 2022-12-03 | by ( Deena Beasley | ) www.reuters.com time to read: +3 min

LOS ANGELES, Dec 3 (Reuters) - Amgen Inc's (AMGN.O) experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday. The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said. The drug was developed from work at Amgen to identify genetic signals associated with lower fat mass and body weight, and also healthy metabolic profiles, explained Saptarsi Haldar, head of cardiovascular metabolic discovery at Amgen.

☆ Atlantia set to be delisted as buyout bid reaches 90% threshold
▼ + stars: | 2022-11-24 | by ( Hadeel Al Sayegh | ) www.reuters.com time to read: +1 min

MILAN, Nov 24 (Reuters) - A buyout offer launched by the Benetton family and U.S. investment fund Blackstone (BX.N) for Italy's Atlantia (ATL.MI) has reached the 90% threshold for the deal to proceed and trigger the company's delisting, the bidders said on Thursday. The bid initially failed to reach the threshold but was then reopened for another five days and closes on Friday. The bidders' vehicle named Schema Alfa said in a statement the planned delisting would happen "as soon as possible in the following weeks". The enterprise value of the deal was around 54 billion euros ($56.32 billion) based on Atlantia's debt level at the end of last year. Atlantia shares closed at 22.95 euros on Wednesday, just below the 23 euros per share Schema Alfa is offering to pay.

☆ Vodafone sells slice of Vantage Towers to KKR, other investors
▼ + stars: | 2022-11-09 | by ( ) www.reuters.com time to read: +1 min

[1/2] Trading information for KKR & Co is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., August 23, 2018. REUTERS/Brendan McDermidLONDON, Nov 9 (Reuters) - Vodafone (VOD.L) said it would sell a portion of its majority stake in wireless towers unit Vantage (VTWRn.DE) to private equity firms GIP and KKR (KKR.N), and use the minimum proceeds of 3.2 billion euros to pay down its debt. The British telecoms group said its would create a new joint venture with the investors, which would result in the deconsolidation of its 81.7% stake. The joint venture would also buy out the minority shareholders in Frankfurt-listed Vantage, it said on Wednesday. Shares in Vantage jumped 7.8%, while Vodafone was broadly flat.

☆ New obesity drugs win support of doctors and insurers, which could lift these pharma names even higher
▼ + stars: | 2022-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

They are also increasingly being prescribed by doctors and covered by insurers – a win for patients and for investors. According to Novo Nordisk , the maker of weight-loss drug Wegovy, about 80% of anti-obesity medications are being covered by health insurers, Meacham said. Novo's semaglutide is branded Wegovy as a weight-loss treatment and Ozempic for the treatment of type 2 diabetes. When combined with lifestyle modifications, patients taking Wegovy can sustain a 15% weight loss , according to late-stage clinical trial data. Eli Lilly has a competing drug, Mounjaro, that uses both GLP-1 and a second incretin, glucose-dependent insulinotropic polypeptide, or GIP.

☆ Global Infrastructure Partners in talks over MSC investment in train operator Italo, papers report
▼ + stars: | 2022-10-15 | by ( ) www.reuters.com time to read: +1 min

MILAN, Oct 15 (Reuters) - U.S.-based Global Infrastructure Partners (GIP) is in exploratory talks with Italian shipping group MSC for a possible investment in GIP's railway operator Italo, two Italian newspapers reported on Saturday. An MSC spokesperson said the company did not comment on media speculation, while GIP did not immediately reply to an email request for comment. The deal would value Italo at 4 billion euros excluding debt, the paper said. A potential deal could see Italo expand in the freight transport sector, but the feasibility and growth potential of such an endeavour was still being analysed, the papers added. ($1 = 1.0289 euros)Register now for FREE unlimited access to Reuters.com RegisterReporting by Agnieszka Flak; editing by Clelia OzielOur Standards: The Thomson Reuters Trust Principles.

The likely purchase of the new asset and the $3 billion valuation of the toll road business has not been reported previously. Representatives from Road King did not respond to requests for comment. CVC and Road King's attempts to monetise the toll road business comes at a time of growing global investor interest for infrastructure assets, driven by sovereign, pension and private equity funds chasing long-term returns. Road King, a Chinese property developer, has operated expressways in the country since nearly three decades. It diversified into the Indonesian toll road business in 2019 and its expressways in China and Indonesia span over 600 kilometres in total, according to the company's website.

One of the sources said the bid could be announced before Saturday, as the two partners rush for taking the Italian infrastructure group private after an unsolicited approach by a consortium led by Global Infrastructure Partners (GIP) and Brookfield. Benettons' holding company Edizione, which controls Atlantia with a 33% stake, and Blackstone are expected to set up a new company that will launch the offer for the infrastructure group, the sources said. In March, GIP, Brookfield and Spain's ACS (ACS.MC) approached the Benettons with a proposal to buy the infrastructure group, they said last week. "Edizione and Blackstone are not currently discussing any plan to involve GIP and Brookfield in their bid," one of the sources said. CRT declined to comment; GIC, Global Infrastructure Partners and Brookfield was not immediately available to comment.

Search resuls for: "GIP"

13 mentions found